9-(2-Phosphonylmethoxyethyl)adenine (PMEA) is a potent and selective inhibitor of retrovirus (i.e., human immunodericiency virus) replication in vitro and in vivo. Uptake of PMEA by human MT-4 cells and subsequent conversion to the mono-and diphosphorylated metabolites (PMEAp and PMEApp) are dose-dependent and occur proportionally with the initial extracellular PMEA concentrations. Adenylate kinase is unable to phosphorylate PMEA. However, 5-phosphoribosyl-1-pyrophosphate synthetase directly converts PMEA to PMEApp with a Km of 1.47 mM and a V. that is 150-fold lower than the Vix for AMP. ATPase, 5'-phosphodiesterase, and nucleoside diphosphate kinase are able to dephosphorylate PMEApp to PMEAp, albeit to a much lower extent than the dephosphorylation of ATP. PMEApp has a relatively long intracellular half-life (16-18 hr) and has a much higher affinity for the human immunodeficiency virusspecified reverse transcriptase than for the cellular DNA polymerase a (K1/Ki: 0.01 and 0.60, respectively). PMEApp is at least as potent an inhibitor of human immunodeficiency virus reverse transcriptase as 2',3'-dideoxyadenosine 5'-triphosphate. Being an alternative substrate to dATP, PMEApp acts as a potent DNA chain terminator, and this may explain its anti-retrovirus activity.
Recently, we discovered a group of acyclic nucleoside phosphonate derivatives that exhibit a potent and selective inhibitory effect on the replication of human immunodeficiency virus (HIV) in vitro (1, 2) . The prototype compound, 9-(2-phosphonylmethoxyethyl)adenine (PMEA) , inhibits viral cytopathicity in cells and viral antigen expression in HIV-1-, HIV-2-, and simian immunodeficiency virusinfected and H9 cells at concentrations (i.e., 0.4-2.0 AM) that are well below the toxicity threshold for the host cells (i.e., 40-67 ,uM) (1) (2) (3) (4) . It has also proven effective in several experimental retrovirus infections in mice, cats, and monkeys (2) (3) (4) (5) (6) (7) (8) . PMEA also protects mice against an acute lethal herpes simplex virus (HSV) infection (5, 9) , has proved beneficial in the treatment of seropositive feline immunodeficiency virus-infected field cats with signs of opportunistic herpetic infections (8) , and is effective against experimental equine herpes virus and cytomegalovirus (CMV) infection in mice (10, 11) . PMEA is rather unique in that it has antiretroviral and antiherpetic properties and thus may be useful in AIDS patients for the treatment of the opportunistic herpesvirus (HSV, CMV, etc.) infections and the underlying retroviral disease.
Investigations have now been undertaken to gain a better insight in the cellular metabolism and mechanism of anti-HIV action of PMEA. PMEA has not been previously studied for its metabolic fate within the cell. Nor has its interaction with viral or cellular enzymes been examined. Our data have revealed that (i) PMEA may be directly converted intracellularly to its diphosphorylated derivative PMEApp, (ii) this phosphorylation is accomplished by 5-phosphoribosyl-1-pyrophosphate (PRPP) synthetase, (iii) PMEApp is targeted at the HIV reverse transcriptase (RT), and (iv) PMEApp acts as a chain terminator of the RT reaction.
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primer, served as the template in a Sanger sequencing reaction using the RT of HIV or avian myeloblastosis virus (AMV). The reaction mixtures contained 60 mM Tris-HCl (pH 8.3), 75 mM NaCi, 7.5 mM MgCl2, and 0.5 mM dithiothreitol. Separate termination mixtures (6 p.l) were prepared for each 2',3'-dideoxynucleotide. The 24 Ci/mmol), 0.01 unit of poly(U)-oligo(dA)12_18, 0.03% Triton X-100, 10 ,ul of PMEApp solution (containing various concentrations of the compound), and 1 p.l of the RT preparation. The reaction mixtures were incubated at 37°C for 15 min, at which time 100 p.l of calf thymus DNA (150 pug/ml), 2 ml ofNa4P207 (0.1 M in 1 M HCl), and 2 ml of trichloroacetic acid (TCA) (10%o, vol/vol) were added. The solutions were kept on ice for 30 min, after which the acid-insoluble material was washed and analyzed for radioactivity.
In the HIV RT assays in which the effect of late addition ofPMEApp was monitored, the [3H]dATP concentration was invariably 2.5 p.M. PMEApp (0.5 ,uM) was added at 3 min or 7.5 min after initiation of the reaction. The RT reaction in the absence or presence of the test compound was followed for 27 min and an aliquot was taken every 3 min for precipitation with 10% TCA and analysis of the acid-insoluble material for radioactivity.
In the calf thymus DNA polymerase a assays, activated calf thymus DNA (Pharmacia) served as the template. The reaction mixture (40 ,ul) contained 20 In a second set of experiments, 0.5 ,M PMEApp was added at 3 and 7.5 min after initiation of the RT reaction (Fig.  2 ). Immediately after PMEApp had been added, the RT reaction ceased to proceed linearly and leveled off almost completely (Fig. 2) . When poly(A)-oligo(dT) is used as the template/primer, [3H]dTMP incorporation is not affected by the addition of PMEApp (data not shown).
DNA Chain Termination by PMEApp and ddATP. PMEApp and ddATP were compared for their DNA chainterminating effects in a Sanger sequencing reaction using an M13 mp19 (+)-strand DNA: 17-base M13 template/primer and the RTs from either HIV or AMV (Fig. 3) . The 2',3'-dideoxynucleotides ddATP, ddCTP, ddGTP, and ddTTP act as potent DNA chain-terminating agents in the RT reaction when present at 10-fold lower concentrations than their natural 2'-deoxynucleotide counterparts (Fig. 3) . PMEApp proved almost equally inhibitory to the DNA polymerization reaction as ddATP. DNA chain termination by PMEApp occurred at the same sites where ddATP caused DNA chain termination (Fig. 3 ).
Interaction ofPMEA with 5'-Nucleotidase, Adenosine Deaminase (ADA), Adenosine 5'-Monophosphate (AMP) Deaminase, AMP Kinase, and PRPP Synthetase. PMEA was examined as a potential substrate/inhibitor for 5'-nucleotidase, ADA, rabbit muscle AMP deaminase, AMP kinase (myokinase) (using ATP, dATP, and GTP as the phosphate donor), and PRPP synthetase. None 
DISCUSSION
PMEA is a potent and selective inhibitor of the replication of several retroviruses (i.e., HIV-1, HIV-2, simian immunodeficiency virus, feline immunodeficiency virus, murine sarcoma virus) in vitro and in vivo. Our data clearly point to the RT as the molecular target for the antiviral action of PMEA. The diphosphorylated product of PMEA, termed PMEApp, is a potent inhibitor of HIV-1 RT (Ki/Km, 0.01), and, like ddATP, it also acts as a DNA chain terminator at the dAMP sites (Figs. 2 and 3) . Although the kinetics of the PMEAppinhibited RT reaction during the time course of 15 min are nonlinear (in contrast to the linearity obtained in the uninhibited RT reaction) (Fig. 2) , no markedly different Kj/Km values were obtained when the RT reaction was followed for only 5 min (Ki/Km, 0.01-0.02). These observations indicate that inactivation of the template-primer by PMEApp is less pronounced than the competitive inhibitory effect of PMEApp (with respect to dATP) on the enzyme under our experimental conditions. This may be essentially due to the excess of template-primer in the RT reaction mixture. Our experiments also revealed that PMEApp does not inactivate the enzyme per se. It does not interfere with the initiation of the RT reaction but rather affects DNA elongation.
[3H]-PMEA is incorporated as such at the 3' end of the DNA. This was verified by hydrolysis ofthe DNA by HC104 and analysis of the products by HPLC.
The metabolism of PMEA clearly differs from that of 2',3'-dideoxyadenosine (16) (17) (18) We found that PMEA could be directly converted to PMEApp through pyrophosphate transfer from PRPP. This reaction is catalyzed by PRPP synthetase, an enzyme that is known to have a very stringent substrate specificity and mainly functions in the "catabolic direction" whereby PRPP and AMP are formed starting from ATP and 5-phosphoribose. In addition to the natural substrates ATP and 5-phosphoribose, only 5-amino4-imidazolecarboxamide riboside triphosphate and 7-deaza-AMP (tubercidin 5'-monophosphate) have ever been reported to act as alternative substrates for this enzyme (20) . PRPP synthetase normally proceeds in the direction of AMP synthesis at an equilibrium ratio of ±9:1 (20) . The fact that invariably higher intracellular concentrations are reached for PMEA than PMEApp may be consistent with these kinetic properties of the enzyme and/or with the relatively high Km (1.47 mM) of PRPP synthetase for PMEA. The extremely low Vmax of PRPP synthetase for the conversion of PMEA to PMEApp may not only account for the slow synthesis of PMEApp from PMEA but also for the relatively long intracellular retention time ofPMEApp after removing PMEA from the extracellular medium. In this respect, it should be noted that PMEApp also has a much lower substrate affinity than ATP for ATP-catabolizing enzymes, including ATPase, 5'-phosphodiesterase, and nucleoside diphosphate kinase (data not shown), and this, in turn, may explain why low levels of PMEAp are generated within PMEA-treated cells (Table 1 , Fig. 1 ). Since the kinetic data found for PMEA against PRPP synthetase are obtained from enzyme experiments in cell-free assays, the exact role of PRPP synthetase in the phosphorylation ofPMEA in intact cells should still be clarified. It cannot be excluded that enzymes other than PRPP synthetase may play an important role in the conversion of PMEA to its antivirally active metabolite PMEApp. PMEAp and PMEApp have a relatively long intracellular half-life. This property contrasts with the short half-life of the 5'-triphosphate derivatives of the pyrimidine 2',3'-dideoxyribosides AZT and D4T (21) but resembles the half-life of the 5'-triphosphate derivative of the purine 2',3'-dideoxynucleoside ddATP (16) . The long intracellular half-life may be the reason for the pronounced anti-retrovirus effects of PMEA in vitro and in vivo.
In conclusion (Fig. 4) , PMEA is postulated to follow a unique metabolic pathway within the MT4 cells. Although not a substrate for purine nucleotide kinase(s) or adenosine (or AMP) deaminases, PMEA could be recognized as a substrate for PRPP synthetase that converts it directly to PMEApp, which, on the one hand, could be dephosphorylated by several enzymes to PMEAp, and, on the other hand, would represent the active form of PMEA. PMEApp could serve as a competitive inhibitor/alternative substrate of the RT reaction and, if incorporated, act as a DNA chain terminator.
